Loading patent…
AssigneeChildren's National Medical Center
InventorsCatherine Mary Bollard, Conrad Russell Y. Cruz, Patrick Hanley
Estimating the term…
Provided herein are activated adoptive T-cell compositions targeting plasma cell dyscrasias such as multiple myeloma and methods of treating plasma cell dyscrasias such as multiple myeloma using such compositions. The T-cell compositions of the present disclosure are activated against a select group of antigens associated with multiple myeloma (MMAAs) and, in certain embodiments, in combination with more widely expressed tumor associated antigens (TAAs). In particular, the T-cell compositions of the present disclosure are directed to the MMAAs selected from B-cell maturation antigen (BCMA), X box Protein 1 (XBP1), CS1, and Syndecan-1 (CD138), or a combination thereof. In certain embodiments, the T-cell composition includes T-cells activated to a TAA selected from preferentially expressed antigen of melanoma (PRAME), Survivin, Wilms' Tumor 1 protein (WT1), and melanoma antigen 3 (MAGE-A3), or a combination thereof.
A method of treating a plasma cell dyscrasia in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a composition, wherein the composition is created by combining two or more T-cell subpopulations that have been separately primed and expanded ex vivo against one or more multiple myeloma associated antigens (MMAAs), wherein the one or more MMAAs are selected from the group consisting of B-cell maturation antigen (BCMA), X-box Protein 1 (XBP1), CS1, and Syndecan-1 (CD138), and wherein each separate T-cell subpopulation is specific for a single MMAA.
A method of treating a plasma cell dyscrasia in a subject in need thereof, comprising administering to the subject (i) a first composition that is created by combining one or more T-cell subpopulations that have been separately primed and expanded ex vivo against one or more multiple myeloma associated antigens (MMAAs) selected from the group consisting of B-cell maturation antigen (BCMA), X-box Protein 1 (XBP1), CS1, and Syndecan-1 (CD138);
Dependencies are inferred from the claim text.